116 related articles for article (PubMed ID: 23466235)
1. Discovery of non-peptide inhibitors of Plasmepsin II by structure-based virtual screening.
Song Y; Jin H; Liu X; Zhu L; Huang J; Li H
Bioorg Med Chem Lett; 2013 Apr; 23(7):2078-82. PubMed ID: 23466235
[TBL] [Abstract][Full Text] [Related]
2. Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids.
Degliesposti G; Kasam V; Da Costa A; Kang HK; Kim N; Kim DW; Breton V; Kim D; Rastelli G
ChemMedChem; 2009 Jul; 4(7):1164-73. PubMed ID: 19437467
[TBL] [Abstract][Full Text] [Related]
3. Pyrrolidine derivatives as plasmepsin inhibitors: binding mode analysis assisted by molecular dynamics simulations of a highly flexible protein.
Luksch T; Blum A; Klee N; Diederich WE; Sotriffer CA; Klebe G
ChemMedChem; 2010 Mar; 5(3):443-54. PubMed ID: 20112327
[TBL] [Abstract][Full Text] [Related]
4. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE
ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222
[TBL] [Abstract][Full Text] [Related]
5. Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design.
McKay PB; Peters MB; Carta G; Flood CT; Dempsey E; Bell A; Berry C; Lloyd DG; Fayne D
Bioorg Med Chem Lett; 2011 Jun; 21(11):3335-41. PubMed ID: 21531557
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of Plasmepsin II-potential antimalarial agents.
Corminboeuf O; Dunet G; Hafsi M; Grimont J; Grisostomi C; Meyer S; Binkert C; Bur D; Jones A; Prade L; Brun R; Boss C
Bioorg Med Chem Lett; 2006 Dec; 16(24):6194-9. PubMed ID: 17000102
[TBL] [Abstract][Full Text] [Related]
7. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
Dali B; Keita M; Megnassan E; Frecer V; Miertus S
Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
[TBL] [Abstract][Full Text] [Related]
8. New benzimidazole derivatives as antiplasmodial agents and plasmepsin inhibitors: synthesis and analysis of structure-activity relationships.
Saify ZS; Azim MK; Ahmad W; Nisa M; Goldberg DE; Hussain SA; Akhtar S; Akram A; Arayne A; Oksman A; Khan IA
Bioorg Med Chem Lett; 2012 Jan; 22(2):1282-6. PubMed ID: 22204908
[TBL] [Abstract][Full Text] [Related]
9. Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring.
Friedman R; Caflisch A
ChemMedChem; 2009 Aug; 4(8):1317-26. PubMed ID: 19472268
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening.
Yi Mok N; Chadwick J; Kellett KA; Hooper NM; Johnson AP; Fishwick CW
Bioorg Med Chem Lett; 2009 Dec; 19(23):6770-4. PubMed ID: 19854048
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.
Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996
[TBL] [Abstract][Full Text] [Related]
12. Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution.
Miura T; Hidaka K; Uemura T; Kashimoto K; Hori Y; Kawasaki Y; Ruben AJ; Freire E; Kimura T; Kiso Y
Bioorg Med Chem Lett; 2010 Aug; 20(16):4836-9. PubMed ID: 20634066
[TBL] [Abstract][Full Text] [Related]
13. Exploring dual inhibitory role of febrifugine analogues against Plasmodium utilizing structure-based virtual screening and molecular dynamic simulation.
Pandey RK; Narula A; Naskar M; Srivastava S; Verma P; Malik R; Shah P; Prajapati VK
J Biomol Struct Dyn; 2017 Mar; 35(4):791-804. PubMed ID: 26984239
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Plasmodium falciparum plasmepsin V by ligand-based virtual screening.
Meissner KA; Kronenberger T; Maltarollo VG; Trossini GHG; Wrenger C
Chem Biol Drug Des; 2019 Mar; 93(3):300-312. PubMed ID: 30320974
[TBL] [Abstract][Full Text] [Related]
15. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
[TBL] [Abstract][Full Text] [Related]
16. De Novo design, synthesis, and in vitro evaluation of a new class of nonpeptidic inhibitors of the malarial enzyme plasmepsin II.
Carcache DA; Hörtner SR; Bertogg A; Binkert C; Bur D; Märki HP; Dorn A; Diederich F
Chembiochem; 2002 Nov; 3(11):1137-41. PubMed ID: 12404641
[No Abstract] [Full Text] [Related]
17. Molecular dynamics simulations of the three dimensional model of plasmepsin II-peptidic inhibitor complexes.
Pranav Kumar SK; Kulkarni VM
Drug Des Discov; 2001; 17(4):293-313. PubMed ID: 11765133
[TBL] [Abstract][Full Text] [Related]
18. Structure-based virtual screening approach to the discovery of novel PTPMT1 phosphatase inhibitors.
Park H; Kim SY; Kyung A; Yoon TS; Ryu SE; Jeong DG
Bioorg Med Chem Lett; 2012 Jan; 22(2):1271-5. PubMed ID: 22115589
[TBL] [Abstract][Full Text] [Related]
19. Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II.
Kiso A; Hidaka K; Kimura T; Hayashi Y; Nezami A; Freire E; Kiso Y
J Pept Sci; 2004 Nov; 10(11):641-7. PubMed ID: 15568678
[TBL] [Abstract][Full Text] [Related]
20. Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design.
Hamada Y; Tagad HD; Nishimura Y; Ishiura S; Kiso Y
Bioorg Med Chem Lett; 2012 Jan; 22(2):1130-5. PubMed ID: 22178553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
